Dottikon Es : Shareholders Approve all Proposals of the Board of Directors
November 27, 2020 at 11:55 am EST
Share
MEDIA RELEASE
Dottikon, November 27, 2020
DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors
Dottikon, Switzerland, November 27, 2020 - Due to the coronavirus pandemic, DOTTIKON ES HOLDING AG's Extraordinary General Meeting took place without the physical presence of the shareholders, who sent in their voting instructions electronically or via mail and approved all proposals of the Board of Directors. The 682 shareholders who participated in the vote represented 1'171'935 voting rights and therefore 96.2% of the total of 1'218'269 registered shares with voting rights.
The proposed share split in the ratio of 1:10 (from nominal value CHF 0.10 to CHF 0.01) was approved by the General Meeting. The first trading day after the share split with the new security number 58258171 and the new ISIN CH0582581713 will be December 4, 2020. The General Meeting also approved the building of additional options to support growth with authorized share capital of up to ten percent of the current share capital.
DOTTIKON ES manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. Its safety culture created over the past 105 years guides the innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing in order to challenge, tighten, or shorten conventional chemical synthesis routes, improve selectivities, yields, and purities, and reduce waste. The versatile technology and equipment portfolio is used, maintained, and continuously expanded to design, develop, and optimize chemical processes and technical manufacturing procedures for the rapid scale-up from kilograms to multi- tons in order to produce and deliver the respective market volumes.
DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development as well as clear and transparent data and process documentation and customer communication.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Dottikon ES Holding AG published this content on 27 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 November 2020 16:54:08 UTC
Dottikon ES Holding AG is a Switzerland-based holding company that specializes in hazardous chemistry and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industries. Its product range includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, as well as industrial chemicals. Its pharmaceutical products can be found in medications for, among others, heart disease, asthma, high blood pressure and ulcers. Dottikon ES Holding AG's industrial end products include food additives, cosmetics, electro-chemicals, photo-chemicals and agricultural chemicals. The Company also offers distillation plants and thin layer evaporators for the recycling of solvents, as well as high temperature incinerators for the waste treatment of hazardous waste. As of March 31, 2012, the Company had two wholly owned subsidiaries: DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG. It also held a 33.9%-stake in SYSTAG, System Technik AG.
DOTTIKON ES HOLDING AG 
